Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) announced on Tuesday that its CEO, Kelvin Cooper, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.
The company says that during the conference, Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Lakewood-Amedex Biotherapeutics is developing a novel class of fast-acting, broad-spectrum antimicrobials, called the Bisphosphocin class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others.
Akeso presents positive results from registrational Phase III study of ivonescimab
US FDA grants orphan drug designation for Lundbeck's asedebart
ABL Diagnostics files bid to acquire IntegraGen
ABEC opens new manufacturing facility in Wilson, NC
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Insilico Medicine doses first patient in Phase III trial of rentosertib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer